Phase II Study of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, and S-1 with Surgery, and Adjuvant Durvalumab Plus S-1 for Resectable Locally Advanced Gastric Cancer

This Phase II study evaluated the efficacy and safety of combining neoadjuvant durvalumab with docetaxel, oxaliplatin, and S-1, followed by surgery and adjuvant durvalumab plus S-1 chemotherapy, for resectable locally advanced gastric cancer.